Michael Rosen, MD
Psychiatry · Roswell, GANPI 1336285261
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 44.6% of the total. Reporting peaked in 2024 at $59,770 and has fallen 79.5% since, to $12,233 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $307.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$63K
- AbbVie$49K
- E.r. Squibb & Sons, L.L.C.$15K
- Tris Pharma Inc$11K
- Supernus Pharmaceuticals, Inc.$740
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
- plus $2K from 17 others
What the payments were for
- Consulting fees$59,93243%
- Speaking & faculty fees$65,00046%
- Travel & lodging$6,6825%
- Food & beverage$8,9396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 84 | $62,628 |
| AbbVie(2 entities) | 166 | $48,859 |
| E.r. Squibb & Sons, L.L.C. | 17 | $14,953 |
| Tris Pharma Inc | 18 | $10,908 |
| Supernus Pharmaceuticals, Inc. | 55 | $740 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $340 |
| Otsuka America Pharmaceutical, Inc. | 13 | $330 |
| Lundbeck LLC | 13 | $250 |
| Almatica Pharma LLC | 12 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $214 |
| Alkermes, Inc. | 9 | $200 |
| Ironshore Pharmaceuticals Inc. | 8 | $153 |
| Eisai Inc. | 4 | $142 |
| Idorsia Pharmaceuticals US Inc | 7 | $134 |
| Johnson & Johnson | 6 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| Corium, LLC | 4 | $91 |
| Neos Therapeutics, LP | 5 | $91 |
| Fidia Pharma USA Inc. | 1 | $23 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $17 |
| Almirall LLC | 1 | $17 |
| Sandoz | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$60,830
- VRAYLAR$46,733
- Dyanavel XR$10,797
- Quillichew ER$10,689
- Quillivant$10,689
- Dayvigo$125
- CAPLYTA$124
- COBENFY$109
- REXULTI$102
How this compares
$140,553 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $41,189 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 103 | $3,612 |
| Methylphenidate ErMethylphenidate Hcl | 27 | $3,051 |
| Fluvoxamine Maleate | 29 | $1,171 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $963 |
| Bupropion XlBupropion Hcl | 43 | $872 |
| Ziprasidone Hcl | 14 | $872 |
| Mirtazapine | 32 | $845 |
| Temazepam | 18 | $801 |
| Guanfacine Hcl ErGuanfacine Hcl | 18 | $769 |
| Methylphenidate Hcl | 49 | $682 |
| Paroxetine Hcl | 25 | $617 |
| Clomipramine Hcl | 11 | $570 |
| Fluoxetine Hcl | 40 | $411 |
| Quetiapine Fumarate | 27 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $48,859 | $41,18928 claims |
| Almatica Pharma LLCSertraline Hcl | $222 | $27358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Richard WinerRoswell$103K
- Joel KirsonRoswell$99K
- Alexandra DoddRoswell$54K
- Scot BayRoswell$26K
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.